Tiziana Life Sciences announced the appointment of Matthew Davis, MD, RPh as its new COO. Davis, who also serves as the Chief Medical Officer, will now take on this additional role to further drive the company’s growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim CEO of Tiziana. As the COO, Dr. Davis will be responsible for overseeing Tiziana Life Sciences’ day-to-day operations, including research and development, manufacturing, clinical trials, and commercialization efforts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TLSA:
- Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
- Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
- Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
- Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
- Tiziana Life Sciences announces findings from nasal anti-CD3 mAb treatment